Afamitresgene autoleucel as an effective T-cell therapy for synovial sarcoma and liposarcoma

1. Overall response rate to afami-cel in both groups was 37%. 2. The majority of adverse-events were moderate in nature with no treatment-related deaths. Evidence Rating Level: 1 (Excellent) Study Rundown: Synovial sarcoma and myxoid round cell liposarcoma are rare, chemo-refractory malignancies with a poor prognosis once metastasized. Current treatment regimens are limited, and a

Related Keywords

United States ,Canada , ,Rating Level ,Advanced Alveolar Soft Part ,Between Dec ,Afamitresgene Autoleucel ,Chimeric Antigen Receptor Cart Cell Therapy ,Immunotherapy ,Liposarcoma ,Oncology ,Sarcoma ,Synovial Sarcoma ,Chronic Disease ,